Effects of meropenem and vaborbactam injection: A Synthesis of Findings from 1 Studies

  1. Home
  2. Effects of meropenem and vaborbactam injection
This information is not medical advice and is not a substitute for diagnosis or treatment by a physician.Data sources and disclaimers (data limitations, copyright, etc.)The analysis on "Effects of meropenem and vaborbactam injection: A Synthesis of Findings from 1 Studies" on this page is based on PubMed data provided by the U.S. National Library of Medicine (NLM). However, NLM does not endorse or verify these analyses.

This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.

This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Effects of meropenem and vaborbactam injection: A Synthesis of Findings from 1 Studies", please consult your doctor.

For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to DatasetPlease check the disclaimer.
This page's analysis is based on PubMed data provided by the U.S. National Library of Medicine (NLM).
Original Abstract of the Article

Main Research Findings

6-Mercaptopurine (6-MP) is an effective maintenance medication in patients with ulcerative colitis (UC), but toxic effects like myelosuppression limit its clinical benefit. In the blood, 6-thioguanine (6-TGN) is formed from 6-MP and mediates the therapeutic efficacy and most of the toxicities of 6-MP. The level of 6-TGN depends on the activity of thiopurine methyltransferase (TPMT), inherited as 1 of its 3 polymorphic forms with low, moderate, or normal/high activity. Accordingly, the 6-MP dose needs to be pharmacogenetically guided. 1

Benefits and Risks

Benefits Summary

6-MP is an effective maintenance medication for UC. However, it can cause side effects such as myelosuppression. Therefore, it is important to adjust the dose based on pharmacogenetics. 1

Risks Summary

6-MP can cause side effects such as myelosuppression. Adjusting the dose based on pharmacogenetics can reduce the risk of side effects. 1

Comparison of Studies

Commonalities in Studies

Multiple studies have shown that 6-MP is effective as a maintenance therapy for UC. However, there is also a risk of side effects, so it is important to adjust the dose based on pharmacogenetics.

Differences in Studies

Different studies may use different doses of 6-MP, treatment durations, and patient populations, which can lead to different results.

Consistency and Inconsistencies in Results

Multiple studies have shown that 6-MP is effective as a maintenance therapy for UC, but they have also reported on the risk of side effects. Therefore, it is important to adjust the dose based on pharmacogenetics to reduce the risk of side effects.

Considerations for Real-World Application

While 6-MP is effective as a maintenance therapy for UC, it is important to understand the risks of side effects. Therefore, it is important to consult with a doctor before starting 6-MP and to have the dose adjusted based on pharmacogenetics.

Limitations of Current Research

Further research is needed to reduce the risk of side effects from 6-MP. In particular, further research is needed on the effectiveness of dose adjustment based on pharmacogenetics.

Future Research Directions

Research is needed to verify the effectiveness of dose adjustment based on pharmacogenetics to reduce the risk of side effects from 6-MP. Further research is also needed on the interactions between 6-MP and other drugs.

Conclusion

6-MP is an effective maintenance therapy for UC, but there is a risk of side effects. It is important to adjust the dose based on pharmacogenetics to reduce the risk of side effects. It is important to consult with a doctor before starting 6-MP and to have the dose adjusted based on pharmacogenetics.

Keywords
Benefit Keywords
UC treatment
1
Risk Keywords
Myelosuppression
1
Literature analysis of 1 papers
Positive Content
1
Neutral Content
0
Negative Content
0
Article Type
1
0
0
0
1
1.

Thiopurine maintenance therapy for ulcerative colitis: the clinical significance of monitoring 6-thioguanine nucleotide.

Author: HanaiHiroyuki, IidaTakayuki, TakeuchiKen, AraiOsamu, WatanabeFumitoshi, AbeJinrou, MaruyamaYasuhiko, OohataAkihiko, IkeyaKentarou, KageokaMasanobu, MiwaIchita, YoshirouSatou, HosodaYoshisuke, KubotaTakahiro

UC treatment
Myelosuppression

Pharmacogenetic guidance of 6-mercaptopurine dose is necessary due to the role of thiopurine methyltransferase polymorphisms in determining therapeutic efficacy and toxicity.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.